한글목차

세계의 바이오마커 시장 규모는 2023년에 464억 달러로 평가되었고, 2024년부터 2033년까지 CAGR 11.2%로 성장할 전망이며, 2033년에는 1,342억 달러에 달할 것으로 예측되고 있습니다.

바이오마커는 생물학적 과정, 건강 상태, 치료 개입에 따른 반응에 대한 중요한 정보를 제공하는 측정 가능한 지표입니다. 다양한 체액, 조직 또는 이미지 데이터에서 발견되는 이러한 마커는 질병 진단, 예후 및 모니터링에 중요한 역할을 합니다. 객관적이고 정량 가능한 지표 역할을 하며 임상의가 질병의 존재, 중증도 및 진행도를 평가할 때 도움이 됩니다. 바이오마커는 단백질, 핵산, 대사산물, 영상 파라미터 등 다양한 스펙트럼을 포함하며 생물학적 시스템의 다양한 특성을 반영합니다.

바이오마커 시장은 만성질환의 이환율 상승과 의약품 개발 과정에서 바이오마커의 높은 채용률로 예측 기간 동안 큰 성장을 기록할 것으로 예상됩니다.

만성 질환 증가는 바이오 마커 시장의 성장을 가속하는 매우 중요한 요인으로 부상하고 있습니다. 최근, 심혈관 질환, 암, 당뇨병, 신경 퇴행성 질환 등의 유병률이 세계적으로 급상승하고 있습니다. 예를 들어 세계보건기구(WHO)의 2024년 보고서에 따르면 2050년에는 3,500만명 이상의 암 환자가 새롭게 진단될 것으로 추정되고 있습니다. 이 급증은 앉아있는 라이프 스타일, 건강에 해로운 식생활, 노화 등 여러 요인으로 인해 발생합니다. 만성질환이 건강관리 시스템에 큰 부담을 주고 있는 가운데, 효과적인 질병관리를 위해 조기 및 정확한 진단이 중시되게 되었습니다.

바이오마커는 생물학적 과정과 상태를 보여주는 측정 가능한 지표이며, 개인의 생리학적 상태에 대한 귀중한 인사이트를 제공함으로써 질병 진단에 중요한 역할을 합니다. 바이오마커는 조기 발견, 위험 평가, 질병 진행 모니터링을 용이하게 하고 적시 개입과 개인화된 치료 전략을 가능하게 합니다. 예를 들어 미국의 생명 공학 회사인 Guardant Health는 Guardant360 CDx 검사를 제공합니다. Guardant360 CDx 검사는 모든 고체 암에 대한 완전한 게놈 검사로 FDA에 승인되었습니다. 이 검사는 기본 혈액 검사 후 7일 이내에 종합적인 게놈 검사 결과를 제공하고 의사가 충분한 정보를 얻은 후 치료법을 선택하는 데 도움이 됩니다. 게다가 유전체학, 단백질체학, 메타보로믹스의 기술 진보는 임상에서 사용되는 바이오마커의 범위를 넓혀 다양한 질병의 진단에 있어서 효능을 향상시키고 있습니다. 따라서 만성 질환의 이환율 증가는 시장 성장을 가속할 것으로 예상됩니다.

의약품 개발 과정에서 바이오마커의 채용 급증은 바이오마커 시장의 성장을 가속하는 매우 중요한 요소입니다. 바이오마커는 생물학적 과정과 치료 개입에 대한 반응의 측정 가능한 지표로 정의되며 의약품 개발 과정에서 필수적인 도구가 되었습니다. 바이오마커는 생물의 생리학적 및 분자생물학적 상태에 대한 정확하고 실시간 정보를 제공할 수 있기 때문에 제약회사의 창약 및 약제 개발에 접근하는 방법에 혁명을 가져왔습니다. 바이오마커는 전임상시험부터 임상시험까지 다양한 단계에서 신약의 효능, 안전성, 잠재적인 부작용을 객관적으로 평가하는 수단을 제공합니다. 이를 통해 의약품 개발 타임라인을 가속화하고 성공 확률을 높일 수 있습니다. 예를 들어, 국립의학 도서관에 의한 2020년 보고서에 따르면, 바이오마커는 창약과 개발의 모든 단계에서 널리 이용되고 있습니다. 바이오마커의 활용은 의약품, 개발, 승인 과정을 보다 효율적으로 만들 수 있는 잠재력을 가지고 있습니다. 따라서 창약 개발 프로세스에 있어서의 바이오마커 채용 증가는 시장의 성장에 크게 공헌할 것으로 기대되고 있습니다.

그러나 데이터 보안과 개인 정보 보호에 대한 우려가 시장 성장을 억제하는 주요 우려로 떠오르고 있습니다. 생명과학 업계는 환자 기록, 임상시험 정보, 게놈 데이터 등 기밀성이 높은 방대한 데이터의 수집, 보관, 분석에 크게 의존하고 있습니다. 헬스케어 프로세스의 디지털화가 진행되고 있으며, 클라우드 컴퓨팅이나 빅데이터 분석 등의 첨단 기술이 채용됨에 따라 데이터 유출이나 무단 액세스의 위험이 높아지고 있습니다. 따라서 데이터 보안 및 개인정보 보호 문제가 시장 성장을 억제할 것으로 예상됩니다.

또한 개발 비용이 높을수록 시장 성장을 억제할 수 있습니다. 바이오마커의 발견과 검증에는 상당한 연구개발비가 듭니다. 바이오마커의 개발과 검증에 드는 비용이 높은 것은 특히 중소기업에서 바이오마커의 채용에 부정적인 영향을 미칩니다.

바이오마커 시장은 유형, 용도, 서비스, 지역에 따라 구분됩니다. 유형별로는 유효성 바이오마커, 안전성 바이오마커, 검증 바이오마커로 나뉩니다. 용도별로는 리스크 평가, 분자진단 개발, 질병 진단, 창약 및 시장 개척, 제제화, 법의학 용도, 기타로 나눌 수 있습니다.

서비스별로는 제약 및 샘플 조제, 어세이 개발, 바이오마커 밸리데이션 및 검사, 기타 서비스로 분류됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(프랑스, 독일, 이탈리아, 스페인, 영국, 기타 유럽), 아시아태평양(중국, 일본, 인도, 한국, 호주 및 기타 아시아태평양), 아시아태평양(브라질, 일본, 인도, 한국, 호주, 아라비아 및 기타 아시아태평양)에서 분석됩니다.

이해관계자를 위한 주요 이점

• 본 보고서는 2023년부터 2033년까지의 바이오마커 시장 분석 시장 부문, 현재의 동향, 추정 및 동향 분석, 역학을 정량적으로 제공하여 바이오마커 시장의 유력한 시장 기회를 특정합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해관계자들이 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자와 공급업체의 힘을 강조합니다.
• 바이오마커 시장의 세분화에 대한 자세한 분석을 통해 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가를 세계 시장에 대한 수익 공헌도에 따라 매핑합니다.
• 시장 기업 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계의 바이오마커 시장 동향, 주요 기업, 시장 부문, 응용 분야 및 시장 성장 전략 분석이 포함되어 있습니다.

이 보고서를 사용자 정의할 수 있습니다.

• 고객의 관심에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 크리스 크로스 부문 분석-시장 규모 및 예측
• 기업 프로파일의 확장 목록
• 과거 시장 데이터
• 주요 기업의 상세(소재지, 연락처, 공급자 및 벤더 네트워크 등을 포함한 엑셀 형식)
• 세계, 지역 및 국가 수준에서 기업의 시장 점유율 분석
• SWOT 분석

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
    • 신약 개발 프로세스에서 바이오마커의 높은 채용률.
    • 만성질환의 급증
    • 법의학 분석에서 바이오마커 채용 증가.
  • 억제요인
    • 바이오마커 개발의 높은 비용
  • 기회
    • 바이오마커 개발을 위한 민간 단체 및 정부 기관의 협력.

제4장 바이오마커 시장 : 유형별

• 개요
• 유효성 바이오마커
• 안전성 바이오마커
• 밸리데이션 바이오마커

제5장 바이오마커 시장 : 용도별

• 개요
• 리스크 평가
• 분자진단제 개발
• 질병 진단
• 창약 및 의약품 개발
• 의약품 제제
• 법의학 용도
• 기타

제6장 바이오마커 시장 : 서비스별

• 개요
• 샘플 준비
• 어세이 개발
• 바이오마커 밸리데이션 및 검사
• 기타 서비스

제7장 바이오마커 시장 : 지역별

• 개요
• 북미
  • 북미의 창약 및 시장 개척 바이오마커 시장 : 유형별
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 유럽의 창약 및 시장 개척 바이오마커 시장 : 유형별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 아시아태평양의 창약 및 시장 개척 바이오마커 시장 :유형별
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 라틴아메리카, 중동 및 아프리카
  • 라틴아메리카, 중동 및 아프리카의 창약 및 시장 개척 바이오마커 시장 : 유형별
  • 브라질
  • 사우디아라비아
  • 남아프리카
  • 기타 라틴아메리카, 중동 및 아프리카

제8장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2023년)

제9장 기업 프로파일

• Abbott Laboratories
• Agilent Technologies Inc.
• Bio-Rad Laboratories, Inc.
• GE Healthcare
• Siemens AG
• Thermo Fisher Scientific
• Qiagen NV
• Merck KGaA
• F. Hoffmann-La Roche AG
• Revvity, Inc.

영문목차

The global biomarkers market size was valued at $46.4 billion in 2023, and is projected to reach $134.2 billion by 2033, growing at a CAGR of 11.2% from 2024 to 2033.

Biomarkers are measurable indicators that provide essential information about biological processes, health conditions, or responses to therapeutic interventions. These markers, found in various bodily fluids, tissues, or even imaging data, play a crucial role in diagnostics, prognosis, and monitoring of diseases. They serve as objectifiable and quantifiable measures, aiding clinicians in assessing the presence, severity, and progression of illnesses. Biomarkers cover a broad spectrum, including proteins, nucleic acids, metabolites, and imaging parameters, reflecting the diverse nature of biological systems.

The biomarkers market is expected to register significant growth during the forecast period owing to a rise in incidence of chronic diseases and high adoption of the biomarkers in the drug development process.

The rise in incidence of chronic diseases has emerged as a pivotal driver propelling the growth of the biomarkers market. In recent years, there has been a noteworthy surge in the prevalence of conditions such as cardiovascular diseases, cancer, diabetes, and neurodegenerative disorders globally. For instance, according to the 2024 report by World Health Organization, it was estimated that over 35 million new cancer cases are expected to be diagnosed in 2050. This surge is attributed to several factors, such as sedentary lifestyles, unhealthy dietary habits, and an aging population. As chronic diseases continue to impose a substantial burden on healthcare systems, there is an increase in emphasis on early and accurate diagnosis for effective disease management.

Biomarkers, which are measurable indicators of biological processes or conditions, play a crucial role in disease diagnosis by providing valuable insights into the physiological state of an individual. Biomarkers facilitate early detection, risk assessment, and monitoring of disease progression, enabling timely intervention and personalized treatment strategies. For instance, Guardant Health, an American biotechnology firm, provides Guardant360 CDx test. Guardant360 CDx test is FDA-approved for complete genomic testing for all solid cancers. The test delivers comprehensive genomic results within 7 days of a basic blood test, helping doctors make informed treatment choices. Furthermore, technological advancements in genomics, proteomics, and metabolomics have broadened the range of biomarkers for clinical use, improving their effectiveness in diagnosis of various diseases. Thus, the rise in the incidence of chronic diseases is expected to drive the growth of the market.

The surge in adoption of biomarkers in the drug development process stands as a pivotal driver propelling the growth of the biomarkers market. Biomarkers, defined as measurable indicators of biological processes or responses to therapeutic interventions, have become indispensable tools in the drug development process. The ability of biomarkers to provide precise and real-time information about the physiological and molecular status of an organism has revolutionized the way pharmaceutical companies approach drug discovery and development. Biomarkers offer a means to objectively assess the efficacy, safety, and potential adverse effects of new drugs at various stages, from preclinical studies to clinical trials. This expedites the drug development timeline and enhances the probability of successful outcomes. For instance, according to the 2020 report by the National Library of Medicine, biomarkers are widely used at every stage of drug discovery and development. Utilization of biomarkers has a potential to make drug discovery, development, and approval processes more efficient. Thus, the rise in adoption of biomarkers in the drug discovery and development procedure is expected to contribute significantly to the growth of the market.

However, data security and privacy concerns have emerged as major concerns that restrain the growth of the market. The life sciences industry relies heavily on the collection, storage, and analysis of vast amounts of sensitive and confidential data, including patient records, clinical trial information, and genomic data. With the increase in digitization of healthcare processes and the adoption of advanced technologies, such as cloud computing and big data analytics, the risk of data breaches and unauthorized access has escalated. Thus, data security and privacy concerns are expected to restrain the growth of the market.

In addition, high development costs might restrain the growth of the market. The discovery and validation of biomarkers involve significant R&D costs. The high cost of developing and validating biomarkers negatively impacts the adoption of the biomarkers particularly in smaller companies.

The biomarkers market is segmented on the basis of type, application, service, and region. By type, the market is divided into efficacy biomarkers, safety biomarkers, and validation biomarkers. By application, the market is divided into risk assessment, development of molecular diagnostic, disease diagnosis, drug discovery & development, drug formulation, forensic application, and others.

By service, it is classified into pharmaceutical & sample preparation, assay development, biomarker validation & testing, and other services. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (France, Germany, Italy, Spain, UK, and rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, rest of LAMEA)

The major players profiled in the report are GE Healthcare, Abbott Laboratories, Inc., Bio-Rad Laboratories, Epistem Ltd., Eisai Co. Ltd., Roche Diagnostics Limited, Thermo Fisher Scientific Inc., Agilent Technologies Inc., Aushon Biosystem, and Siemens AG.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the biomarkers market analysis from 2023 to 2033 to identify the prevailing biomarkers market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the biomarkers market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Criss-cross segment analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)
• Market share analysis of players at global/region/country level
• SWOT Analysis

Key Market Segments

By Type

• Safety Biomarkers
• Validation Biomarkers
• Efficacy Biomarkers

By Application

• Risk Assessment
• Development of Molecular Diagnostic
• Disease Diagnosis
• Drug Discovery and Development
  • Type
  • Clinical Trial - Pre Clinical Phase and Phase 1
  • Clinical Trial Phase 2
  • Clinical Trial Phase 3
  • Clinical Trial Commercial Phase
• Drug Formulation
• Forensic Application
• Others

By Services

• Sample Preparation
• Assay Development
• Biomarker Validation and Testing
• Other Services

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Bio-Rad Laboratories, Inc.
• Thermo Fisher Scientific
• Qiagen N.V
• F. Hoffmann-La Roche AG
• GE Healthcare
• Revvity, Inc.
• Abbott Laboratories
• Siemens AG
• Merck KGaA
• Agilent Technologies Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. High adoption of biomarkers in drug discovery and development process.
    • 3.4.1.2. Surge in prevalence of chronic diseases.
    • 3.4.1.3. Rise in adoption of biomarkers in forensic analysis.
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of development of biomarkers.
  • 3.4.3. Opportunities
    • 3.4.3.1. Collaborative efforts by private and government organizations for development of biomarkers.

CHAPTER 4: BIOMARKERS MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Efficacy Biomarkers
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Safety Biomarkers
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Validation Biomarkers
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: BIOMARKERS MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Risk Assessment
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Development of Molecular Diagnostic
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Disease Diagnosis
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Drug Discovery and Development
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
  • 5.5.4. Drug Discovery and Development Biomarkers Market by Type
    • 5.5.4.1. Clinical Trial - Pre Clinical Phase and Phase 1 Market size and forecast, by region
    • 5.5.4.2. Clinical Trial Phase 2 Market size and forecast, by region
    • 5.5.4.3. Clinical Trial Phase 3 Market size and forecast, by region
    • 5.5.4.4. Clinical Trial Commercial Phase Market size and forecast, by region
• 5.6. Drug Formulation
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country
• 5.7. Forensic Application
  • 5.7.1. Key market trends, growth factors and opportunities
  • 5.7.2. Market size and forecast, by region
  • 5.7.3. Market share analysis by country
• 5.8. Others
  • 5.8.1. Key market trends, growth factors and opportunities
  • 5.8.2. Market size and forecast, by region
  • 5.8.3. Market share analysis by country

CHAPTER 6: BIOMARKERS MARKET, BY SERVICES

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Sample Preparation
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Assay Development
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Biomarker Validation and Testing
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Other Services
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: BIOMARKERS MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Type
  • 7.2.3. Market size and forecast, by Application
    • 7.2.3.1. North America Drug Discovery and Development Biomarkers Market by Type
  • 7.2.4. Market size and forecast, by Services
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Type
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by Services
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Type
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by Services
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Type
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by Services
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Type
  • 7.3.3. Market size and forecast, by Application
    • 7.3.3.1. Europe Drug Discovery and Development Biomarkers Market by Type
  • 7.3.4. Market size and forecast, by Services
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. UK
    • 7.3.5.1.1. Market size and forecast, by Type
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by Services
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Type
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by Services
    • 7.3.5.3. Germany
    • 7.3.5.3.1. Market size and forecast, by Type
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by Services
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Type
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by Services
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Type
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by Services
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Type
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by Services
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Type
  • 7.4.3. Market size and forecast, by Application
    • 7.4.3.1. Asia-Pacific Drug Discovery and Development Biomarkers Market by Type
  • 7.4.4. Market size and forecast, by Services
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Type
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by Services
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Type
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by Services
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Type
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by Services
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Type
    • 7.4.5.4.2. Market size and forecast, by Application
    • 7.4.5.4.3. Market size and forecast, by Services
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Type
    • 7.4.5.5.2. Market size and forecast, by Application
    • 7.4.5.5.3. Market size and forecast, by Services
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Type
    • 7.4.5.6.2. Market size and forecast, by Application
    • 7.4.5.6.3. Market size and forecast, by Services
• 7.5. LAMEA
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Type
  • 7.5.3. Market size and forecast, by Application
    • 7.5.3.1. LAMEA Drug Discovery and Development Biomarkers Market by Type
  • 7.5.4. Market size and forecast, by Services
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Type
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by Services
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Market size and forecast, by Type
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by Services
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Market size and forecast, by Type
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by Services
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Market size and forecast, by Type
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by Services

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

• 9.1. Abbott Laboratories
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Agilent Technologies Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
• 9.3. Bio-Rad Laboratories, Inc.
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
• 9.4. GE Healthcare
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Siemens AG
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Thermo Fisher Scientific
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Qiagen N.V
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Merck KGaA
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. F. Hoffmann-La Roche AG
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Revvity, Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance